Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Post by Ingiboyon May 10, 2023 4:38pm
145 Views
Post# 35441696

RE: RE:RepliCel applies to TSX-V to extend warrants

RE: RE:RepliCel applies to TSX-V to extend warrantsMost companies can't wait to get rid of warrants. They are often a marketing inducement to buy in to PP's.  Generally companies are happy when they expire.  Not Replicel.
As I have mentioned in a previous post the Insiders and large shareholders now own at least  75% of the company and they would certainly love to get rid of us 25%ers.  We were there for the most part in the early days when they needed shreholders but now it is clear that this inside group has a plan and unfortunately they are not sharing it with the rest of us. For a number of years as some of you can remember we were continually asking for corporate updates or any timely information.  When management felt enough pressure they would finally release some vague and often misleading
NR. Now we get nothing.
This is a critical juncture for this company.  It is a virtual make it or break it situation with this ongoing Arbitration which is now 19 months in duration.  You cannot tell me that the insiders don't know what is going on or where this is headed. 
Being in this 25% group doesn't make me very happy at the moment.  I feel like I am standing at the roulette table with all my money on Black waiting for the ball to drop into a slot. If it is red I am wiped out.

<< Previous
Bullboard Posts
Next >>